Verily Health has announced a strategic partnership with Autoimmune Registry Inc. (ARI) to expand research infrastructure supporting the study of autoimmune diseases. The collaboration will combine Verily's patient engagement, data management and analytics capabilities with ARI's longitudinal registry, enabling researchers to investigate relationships between autoimmune conditions, disease progression and treatment outcomes.
An estimated 15 million Americans live with autoimmune diseases, with many experiencing multiple conditions simultaneously. However, existing patient registries typically focus on individual diseases, limiting opportunities to investigate overlapping diagnoses and shared disease characteristics.
Founded in 2016, ARI maintains a cross-disease registry containing more than 5,000 participants across over 100 autoimmune conditions. Its dataset includes patient-reported outcomes, medical histories and comorbidity information, with participation overseen by an Institutional Review Board (IRB) and consented for research purposes.
Under the agreement, Verily will provide infrastructure across three areas:
Patient engagement: Participants can enroll through the Verily Me application and its Lifelong Health Study, supporting ongoing data collection and research participation.
Research infrastructure: Verily Workbench will provide a governed analytics environment, while Verily Exchange will enable controlled data sharing with pharmaceutical companies, academic institutions and research organizations.
Operational support: Verily will manage dataset curation, sensitive information, research engagement and collaboration across healthcare stakeholders.
These capabilities form part of Verily Pre, the company's governed health AI platform.
Stephen Gillett, Chairman and CEO of Verily Health, emphasized the broader applicability of the approach: “Our work with ARI is a model we intend to bring to other disease communities, so that every registry can become a foundation for discovery.”
The partnership also creates opportunities for researchers to examine comorbidity patterns, disease progression and treatment responses across multiple autoimmune conditions using a consented longitudinal cohort.
Beyond autoimmune research, the companies intend to establish a replicable infrastructure model for other patient registries and advocacy organizations, reducing the need to develop independent data management systems.
Verily and ARI anticipate expanding the collaboration through additional data sources and capabilities as registry participation increases.
Click here for the original news story.
